Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...

In a groundbreaking leap forward for cancer therapy, scientists in Japan have created a tiny delivery system that helps powerful antibodies reach hidden targets deep inside cancer cells. These ...

Antibodies have evolved by nature to possess exquisite selectivity for foreign targets to elicit an effective immune response, making particularly promising strides in advancing drug development for ...

Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate ...

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, ...

Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), ...

Researchers have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine three different functions in the ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...

Researchers led by teams at NYU Langone Health and its Perlmutter Cancer Center have reported on the development of antibodies that can selectively target cancer-related mutations in the extracellular ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...